E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000846 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the trial is to estimate the activity of BMS-354825 in de novo adult Ph ALL patients in terms of complete hematological remission CHR rate with or without Full hematological Recovery- FR |
|
E.2.2 | Secondary objectives of the trial |
To evaluate treatment toxicity To estimate the rate of cytogenetic responses To estimate the rate of molecular responses To assess disease-free survival DFS To estimate relapse rate To assess overall survival OS . |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-- Patients with de novo Ph and/or BCR/ABL ALL within 14 days from diagnosis - Age 8805;18 years old - No prior treatment with any anti-leukemic drugs with the exception of steroids for no more than 14 days including the 7-day pretreatment already scheduled in the protocol - WHO performance status 8804;2 - Absence of central nervous system CNS leukemia - Normal serum level of potassium, total calcium corrected for serum albumin magnesium and phosphorus, or correctable with supplements - ALT and AST 8804;2.5 x ULN upper limit of normal range or 8804;5.0 x ULN if considered due to leukemia - Alkaline phosphatase 8804;2.5 x ULN unless considered to leukemia - Serum bilirubin 8804;2 x ULN - Serum creatinine 8804;3 x ULN - Serum amylase 8804;1.5 x ULN and serum lipase 8804;1.5 x ULN - Normal cardiac function - Written informed consent prior to any study procedures being performed.. |
|
E.4 | Principal exclusion criteria |
- Impaired cardiac function, including any one of the following 61607; LVEF Left Ventricular Ejection Fraction 45 as determined by MUGA scan or echocardiogram 61607; Complete left bundle branch block 61607; Use of a cardiac pacemaker 61607; ST depression of 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads 61607; Congenital long QT syndrome 61607; History of or presence of significant ventricular or atrial tachyarrhythmia 61607; Clinically significant resting bradycardia 50 beats per minute 61607; QTc 450 msec on screening ECG using the QTcF formula 61607; Right bundle branch block plus left anterior hemiblock, bifascicular block 61607; Myocardial infarction within 3 months prior to starting BMS-354825 61607; Angina pectoris 61607; Other clinically significant heart disease e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen - Impairment of gastrointestinal GI function or GI disease that may significantly alter the absorption of BMS-354825 e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection - Use of therapeutic warfarin - Acute or chronic liver or renal disease considered unrelated to leukemia - Other concurrent severe and/or uncontrolled medical conditions e.g., uncontrolled diabetes, active or uncontrolled infection that could cause unacceptable safety risks or compromise compliance with the protocol - Treatment with any hematopoietic colony-stimulating growth factors e.g., G-CSF, GM CSF 8804;1 week prior to starting study drug - Patients who are currently receiving treatment with any of the medications listed in Appendix F and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix F have the potential to prolong the QT interval. - Patients who have received any anti-leukemic agents and treatments including steroids for more than 14 days including 7 days pretreatment that is part of the protocol - Patients who have received any investigational drug in the last 2 weeks - Patients who have undergone major surgery 8804;2 weeks prior to starting study drug or who have not recovered from side effects of such therapy - Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of BMS-354825 . Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug - Known diagnosis of human immunodeficiency virus HIV infection HIV testing is not mandatory - Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention - Non compliant to oral medication patients. - Central nervous system CNS involvement. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
HCR with or without FR rate obtained during the BMS induction treatment, whenever achieved by Day 85. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |